Sold as Choledyl. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 14, 2026, FDA lists 7 applications for Oxtriphylline (sold as Choledyl), with 0 new uses approved and 0 published complete response letters.
| Nov 5, 1981 | Choledyl SAANDA 86742 | Warner Chilcott LLC | 13 | Discontinued |
| May 24, 1983 | Choledyl SAANDA 87863 | Warner Chilcott LLC | 13 | Discontinued |
| — | OxtriphyllineANDA 87835 | Watson Labs | 0 | Discontinued |
| — | OxtriphyllineANDA 87866 | Watson Labs | 0 | Discontinued |
| — | Oxtriphylline PediatricANDA 88242 | Morton Grove | 0 | Discontinued |
| — | OxtriphyllineANDA 88243 | Morton Grove | 0 | Discontinued |
| — | CholedylNDA 9268 | Parke Davis | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Parke Davis